Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Erasca Inc (ERAS)

Erasca Inc (ERAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones GlobeNewswire - Mon Jan 12, 7:00AM CST

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015...

ERAS : 9.44 (+13.60%)
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Tue Jan 6, 7:00AM CST

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 9.44 (+13.60%)
Erasca to Present at the 8th Annual Evercore Healthcare Conference GlobeNewswire - Tue Nov 25, 2025

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 9.44 (+13.60%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B FinancialNewsMedia - Wed Nov 19, 2025

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

ONCY : 1.0100 (-3.81%)
IMRX : 4.55 (+2.71%)
ALXO : 1.2950 (-2.63%)
ERAS : 9.44 (+13.60%)
PRLD : 2.15 (-4.87%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B GlobeNewswire - Wed Nov 19, 2025

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...

ONCY : 1.0100 (-3.81%)
IMRX : 4.55 (+2.71%)
ALXO : 1.2950 (-2.63%)
ERAS : 9.44 (+13.60%)
PRLD : 2.15 (-4.87%)
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 GlobeNewswire - Thu Nov 6, 2025

The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043  Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001...

ERAS : 9.44 (+13.60%)
Erasca to Present at Upcoming Conferences in November GlobeNewswire - Tue Nov 4, 2025

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 9.44 (+13.60%)
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference GlobeNewswire - Tue Sep 2, 2025

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...

ERAS : 9.44 (+13.60%)
Erasca Reports Second Quarter 2025 Business Updates and Financial Results GlobeNewswire - Tue Aug 12, 2025

Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust...

ERAS : 9.44 (+13.60%)
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch Newswire.ca - Mon Jun 30, 2025

/CNW/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline....

ONCY : 1.0100 (-3.81%)
CLRB : 3.62 (-3.21%)
INTS : 0.4192 (-1.36%)
ARAY : 0.8682 (+3.25%)
ONC.TO : 1.42 (+2.16%)
ERAS : 9.44 (+13.60%)

Barchart Exclusives

How to Play BABA Stock as Alibaba’s Growth Story Gets a Boost From the Chinese Government Barchart - 2 minutes ago
Alibaba stock is already up 16% for the year following last year's stellar rally. Is the stock still a buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot